Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient

Patrick Joseph Merrill; R Mark Bradburne

doi:10.7812/TPP/21.125

Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient

Perm J. 2021 Dec 14:25:21.125. doi: 10.7812/TPP/21.125.

Authors

Patrick Joseph Merrill¹, R Mark Bradburne²

Affiliations

¹ Department of Cardiology, Riverside Kaiser Hospital, Southern California Permanente Medical Group, Riverside, CA.
² Department of Pulmonology, Riverside Kaiser Hospital, Southern California Permanente Medical Group, Riverside, CA.

Abstract

This case report describes a successful outcome involving a patient with severe COVID-19 viral pneumonia utilizing a novel therapeutic approach with the glycoprotein IIb/IIIa inhibitor, eptifibatide.

Publication types

Case Reports

MeSH terms

COVID-19 Drug Treatment*
Eptifibatide
Humans
Peptides / therapeutic use
Platelet Aggregation Inhibitors / therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex

Substances

Peptides
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Eptifibatide